Hormone receptor-positive breast cancer

This trial is for people with ER-positive, HER2-negative advanced breast cancer whose disease has started to grow in a few spots while on hormone therapy and a CDK4/6 inhibitor. It tests whether adding targeted radiation (SABR) to those spots allows patients to stay on their curr…

Researchers are studying giredestrant, an experimental daily pill, in people with estrogen receptor-positive, HER2-negative early breast cancer. The trial enrolls about 1,500 participants, including some who switch to giredestrant after other treatments. It tracks how many people…

Researchers are testing whether women aged 65 and older with early-stage, lymph node-positive, ER+/HER2- breast cancer can safely skip chemotherapy. Participants receive CDK4/6 inhibitors, with or without endocrine therapy, after surgery. The trial tracks how many women remain fr…

This trial is testing whether a combination of drugs—inavolisib plus fulvestrant, with or without palbociclib—is safe for people with a specific type of advanced breast cancer (HR+, HER2-negative) that has a PIK3CA mutation, and who also have type 2 diabetes. The main focus is on…

This study looks at whether extra education and counseling helps women with HR+/HER2- early breast cancer take their prescribed medication, abemaciclib, more consistently. About 257 women will either receive standard care or additional coaching. The main goal is to see if coachin…

This phase II trial tests whether combining the hormone therapy letrozole with standard chemotherapy before surgery can improve tumor shrinkage in people with ER-positive, HER2-negative breast cancer that grows quickly. Participants receive either six cycles of docetaxel, epirubi…

This trial tests whether adding the investigational drug capivasertib to standard hormone-blocking therapy and a CDK4/6 inhibitor can improve treatment response in people with HR-positive, HER2-negative metastatic breast cancer. Participants receive either the standard treatment …

This early-stage trial is testing an experimental drug called LAE118 in people with advanced solid tumors that have a specific genetic change (PIK3CA mutation). The study will evaluate the drug's safety and tolerability when given alone or combined with other anti-cancer medicati…

This pilot trial tests whether adding the drug alisertib to usual care can help people with advanced HR+/HER2+ breast cancer whose disease has become resistant to standard treatments. Researchers want to see if alisertib can block communication between hormone receptors and HER2,…

This trial tests whether adding an experimental immunotherapy drug (QL1706) to standard hormone therapy can shrink tumors in people with a common type of breast cancer (HR-positive, HER2-negative) that did not respond well to initial chemotherapy. About 40 participants whose tumo…

This trial is testing whether adding an experimental drug called JYP0035 to the standard medicine fulvestrant can help people with a certain type of advanced breast cancer. The study focuses on patients whose tumors have a PIK3CA gene mutation and who have already tried hormone t…

This trial is testing whether the drug trastuzumab deruxtecan (T-DXd) can help people with a certain type of advanced breast cancer. The study focuses on patients whose tumors were originally classified as HER2-null (no HER2 protein) but were re-scored as HER2-ultralow using arti…

This study tests an experimental drug called ATX-898 in people with advanced solid tumors that have spread or cannot be removed by surgery. The trial has two parts: first, ATX-898 is given alone to find the safest dose; second, it is combined with other anti-cancer drugs to see i…

This trial is testing whether a special PET scan can help predict how well the drug elacestrant works in people with a certain type of advanced breast cancer (ER-positive, HER2-negative) that has not responded to prior hormone therapy. All participants will take elacestrant daily…

This trial is testing an experimental therapy called CRG-150, which uses a patient's own immune cells that have been gene-edited to potentially fight cancer. The study includes adults with advanced HR-positive/HER2-negative breast cancer, triple-negative breast cancer, or prostat…

This phase 2 trial is testing whether adding anlotinib to a combination of culmerciclib and endocrine therapy can control disease in people with HR-positive, HER2-negative breast cancer that has spread to the brain. The study enrolls adults with newly diagnosed or progressing bra…

This study tests a new drug, prifetrastat, combined with fulvestrant for people with advanced HR+/HER2- breast cancer that has stopped responding to standard hormone therapy and CDK4/6 inhibitors. About 51 participants will receive the combination to see if it can shrink tumors o…

This trial is testing an experimental drug called GB268, a tri-specific antibody that targets three key pathways involved in cancer growth. It is being studied alone or in combination with other treatments in people with locally advanced or metastatic breast cancer. The goal is t…

This study follows young women with hormone-sensitive breast cancer who stayed premenopausal or resumed menstruation after chemotherapy. Researchers are investigating whether adding two years of ovarian function suppression to standard tamoxifen therapy can lower the chance of ca…

This trial investigates whether adding neratinib, a drug that blocks HER2/3/4 proteins, to standard hormone therapy can improve disease control in people with metastatic ER+/HER2- breast cancer that has stopped responding to first-line endocrine therapy. Participants will receive…

This trial tests a planned sequence of treatments for people with advanced or metastatic HER2-positive and hormone receptor-positive breast cancer. Participants first receive T-DXd (Enhertu) plus pertuzumab, then switch to a maintenance combination of palbociclib, endocrine thera…

This study tests whether adding a new oral drug called fulvestaciclib to standard anti-HER2 and hormone therapy can help people with HR+/HER2+ advanced breast cancer live longer without their disease getting worse. Some participants receive the combo after initial chemotherapy, w…

This phase 3 trial tests whether monitoring tumor DNA in the blood (ctDNA) can help doctors switch hormone therapy earlier in people with ER+/HER2- metastatic breast cancer. Participants whose ctDNA levels rise—before any symptoms or scans show progression—are randomly assigned t…

This trial compares how well patients tolerate dalpiciclib versus abemaciclib or ribociclib when each is combined with standard hormone therapy for high-risk HR+/HER2- early breast cancer. About 456 patients who have completed initial local treatment will be randomly assigned to …

This trial is studying a combination of two targeted drugs, patritumab deruxtecan and trastuzumab deruxtecan, for people with a specific type of advanced breast cancer that is hormone receptor positive and has low or ultra-low levels of a protein called HER2. The study aims to fi…

This trial tests an experimental drug called SYH2095, taken as a daily pill, in people with advanced solid tumors that have no effective standard treatment. The drug blocks a protein (KAT6A/B) involved in cancer cell growth. The study aims to find a safe dose and check for early …

This study tests whether a combination of three drugs—kumorixilib, capecitabine, and letrozole—given before surgery can slow or shrink tumors in people with HR-positive, HER2-negative breast cancer. Participants take the drugs for six 28-day cycles, then have surgery. The main go…

This phase 2 trial investigates whether tirzepatide, a drug used for weight loss and diabetes, can slow tumor growth in people with early-stage hormone-receptor-positive breast cancer. Participants receive tirzepatide alone, the standard hormone therapy letrozole alone, or both t…

This Phase 2 trial tests BL0175, a nano-medicine that delivers cancer-fighting drugs directly into tumors. It enrolls 120 postmenopausal women with HR+/HER2- advanced breast cancer. Researchers compare different doses to find the safest and most effective one for shrinking tumors…

This study tests whether adding an immune-boosting drug called eftilagimod alpha to standard chemotherapy before surgery can completely eliminate tumors in people with early-stage hormone receptor-positive, HER2-negative breast cancer. About 50 participants will receive the drug …

This phase II trial is testing a three-drug combination given before surgery for people with intermediate-to-high risk HR-positive, HER2-low breast cancer. Participants first take dalpiciclib (a pill) plus an aromatase inhibitor (another pill) for about 4 months, followed by infu…

This study looks at whether a structured support program can help people with early-stage, hormone-positive breast cancer stick to their ribociclib medication (taken with an aromatase inhibitor). About 90 participants will be split into two groups: one gets standard care, the oth…

This phase 2 trial is testing a combination of three drugs—inavolisib, ribociclib, and fulvestrant—in 160 Chinese women with a specific genetic mutation (PIK3CA) in hormone receptor-positive, HER2-negative advanced breast cancer that has stopped responding to endocrine therapy. T…

This study tests a combination of two drugs, zongertinib and fulvestrant, in people with advanced breast cancer that is hormone receptor-positive and HER2-negative but has a specific HER2 gene mutation. The goal is to see if the combination shrinks tumors. About 25 adults will ta…

This Phase 2 trial will enroll 100 young women (ages 18-45) with hormone receptor-positive breast cancer who are already on a 3-month GnRH injection for ovarian suppression. Half will switch to a monthly injection, while the other half stays on the 3-month schedule. The study aim…

This study tests whether starting abemaciclib at a lower dose and gradually increasing it can reduce early side effects like diarrhea and fatigue in people with high-risk HR+/HER2- breast cancer. The goal is to help more patients stay on their full treatment plan. About 86 partic…

This study tests whether combining brain radiation with a targeted drug (dalpiciclib) and hormone therapy can help control breast cancer that has spread to the brain in people with HR-positive/HER2-negative disease. About 46 participants will receive the combination and be follow…

This study looks at how well a drug called inavolisib works in real-world settings for people with a certain type of advanced breast cancer (HR-positive, HER2-negative, with a PIK3CA mutation). About 100 participants will take inavolisib along with hormone therapy, sometimes with…

This phase 3 trial compares an injectable form of letrozole (given every 3 months) to the standard daily oral pill, both combined with ribociclib, in 300 postmenopausal women with advanced HR-positive, HER2-negative breast cancer. The goal is to see if the injection works as well…

This early-stage trial tests a new oral drug called HLX97 in 138 people with advanced solid tumors (breast, prostate, or lung cancer) that have stopped responding to standard treatments. The main goals are to check safety, find the right dose, and see if the drug can slow tumor g…

This phase 2 trial tests a new drug called HLX43 in 60 people with a common type of advanced breast cancer (HR+ HER2-) that has worsened despite standard hormone therapy. The drug is an antibody-drug conjugate that targets PD-L1 to deliver chemotherapy directly to cancer cells. T…

This study tests a new approach for women with a common type of early breast cancer (HR+/HER2-). Instead of standard chemotherapy before surgery, some participants will receive a combination of hormone therapy and a targeted drug (abemaciclib) based on their tumor's gene test res…

This early-phase trial will test the safety and tolerability of combining a CDK4/6 inhibitor (abemaciclib) with radiation therapy after surgery in 30 women with HR+/HER2- high-risk breast cancer. The study aims to find the highest safe dose of the drug when used alongside radiati…

This phase 2 trial tests a combination of two drugs—entinostat and oral paclitaxel—in 50 people with HR-positive, HER2-negative advanced breast cancer who have already tried 2 to 4 prior treatments. The goal is to see if the combo can delay cancer growth. Participants take both d…

This study looks at whether a combination of ribociclib (a targeted drug) and hormone therapy can be as effective as chemotherapy followed by the same combo for people with a common type of early breast cancer (HR+/HER2-). Only patients whose blood tests show no signs of cancer D…

This study tests whether taking letrozole, a hormone therapy pill, for one year before surgery can shrink tumors and clear cancer from lymph nodes in postmenopausal women with early-stage, hormone-sensitive breast cancer. All 126 participants will take letrozole daily and then ha…

This study tests whether taking two drugs (imlunestrant and abemaciclib) before surgery can shrink tumors in people with a common type of breast cancer (ER+/HER2-). About 189 women aged 18-75 with early-stage breast cancer will join. The treatment is guided by a marker called Ki6…

This Phase 3 trial tests whether adding the experimental drug NTQ1062 to standard hormone therapy (fulvestrant) can slow or stop the growth of advanced HR+/HER2- breast cancer in people whose cancer has returned or worsened after hormone therapy. The study includes 210 adults wit…

This study tests whether adding famitinib to SHR-A1811 works better than SHR-A1811 alone for people with a certain type of advanced breast cancer (HR+/HER2-) that no longer responds to CDK4/6 inhibitors. About 248 women aged 18-70 will take part. The goal is to see if the combina…

This study looks at two powerful drugs, sacituzumab govitecan (SG) and trastuzumab deruxtecan (T-DXd), for people with a certain type of advanced breast cancer (HER2-low/TROP2-high). The goal is to find out which drug works best when given first and how to switch if the first sto…

This study tests a new two-drug combination (JSKN016 plus D-0502) in 60 people with advanced hormone receptor-positive, HER2-negative breast cancer whose disease worsened after standard hormone therapy. The goal is to see if the combination is safe and shrinks tumors. Participant…

This phase II trial tests whether adding the drugs SHR-A1811 and/or adebrelimab to standard chemotherapy can improve outcomes for people with HR-positive, HER2-low early-stage breast cancer. About 249 participants will receive either chemo alone, chemo plus adebrelimab, or a sequ…

This study looks at 4,000 women aged 50 or younger with a common type of early breast cancer. Researchers want to see if hormone therapy plus ovarian function suppression works as well as chemotherapy for those with certain genetic test scores. The goal is to find out who can saf…

This study tests a new drug combination (SHR-A1811 plus pertuzumab) given before surgery to women with early or locally advanced HR-positive, HER2-positive breast cancer. The goal is to see if this treatment can eliminate all cancer cells in the breast and lymph nodes by the time…

This Phase 2 trial tests a new drug called SHR-A1811, alone or with hormone therapy (letrozole), against standard chemotherapy in 120 women with early-stage HR-positive, HER2-low breast cancer. The goal is to see if these combinations can shrink tumors before surgery more effecti…

This study tests whether a combination of two drugs (fulvestrant and ribociclib) works better than standard treatments for people with a certain type of advanced breast cancer (HR+, HER2-). The cancer has returned after the patient finished a prior course of CDK4/6 inhibitors. Ab…

This study tests whether monitoring tumor DNA in the blood (ctDNA) and treating with abemaciclib can prevent breast cancer from coming back. 30 people with HR+/HER2- breast cancer who have finished standard treatment will be followed. If ctDNA is detected, they will receive abema…

This study tests whether adding targeted radiation (SBRT) to standard chemotherapy and immunotherapy before surgery can improve outcomes for people with a common, high-risk breast cancer type (HR+/HER2-). About 302 participants will be randomly assigned to receive either chemo-im…

This study tests whether adding entinostat to fulvestrant can help control advanced breast cancer in people whose disease has worsened after standard hormone therapy and CDK4/6 inhibitors. About 50 women aged 18-75 with HR+/HER2- cancer will receive the combination. The main goal…

This phase II trial tests whether adding two immunotherapy drugs (iparomlimab and tuvonralimab) to standard chemotherapy before surgery can improve tumor response in 30 patients with HR+/HER2- breast cancer. The study uses a two-stage design to check if enough patients achieve a …

This early-stage trial tests a drug called sacituzumab govitecan combined with hormone therapy in 12 people with HR-positive, HER2-negative metastatic breast cancer that has worsened after CDK4/6 inhibitor treatment. The main goal is to check safety and side effects, while also l…

This study tests a new drug called SC-101 in 120 people with advanced breast cancer (triple-negative or hormone-receptor-positive) that has a specific gene change called NECTIN4 amplification. Participants receive the drug once a week through an IV. The goal is to see if the drug…

This study tests whether adding radiation before surgery to standard chemotherapy can shrink tumors more effectively in people with locally advanced breast cancer. It includes 50 participants with Luminal or triple-negative subtypes who did not respond well to initial chemo. The …

This study looks at the best order to give two powerful antibody-drug conjugates (ADCs) — T-DXd and SG — to people with a common type of advanced breast cancer (HR+/HER2-). After standard hormone therapy stops working, doctors are unsure which drug to use first. The study will en…

People with hormone receptor-positive, HER2-negative advanced breast cancer often start treatment with a CDK4/6 inhibitor plus an aromatase inhibitor. Over time, some tumors develop an ESR1 mutation that can make the aromatase inhibitor stop working. This study takes blood sample…

This early-phase study tests a new imaging agent that targets a protein called TROP2, found on many cancer cells. About 40 adults with metastatic bladder, breast, or lung cancer will receive the agent to see where it goes in the body. The goal is to see if this tracer can help do…

This study looks at whether adding the drug bupropion (Wellbutrin) to standard hormone therapy can help women with early-stage breast cancer who have lost interest in sex. About 100 women will be randomly assigned to receive either their usual hormone therapy alone or with buprop…

This study tests a 6-session telehealth program called STRIDE, which uses cognitive behavioral therapy to help women with hormone-positive breast cancer manage side effects from adjuvant endocrine therapy. Participants will be randomly assigned to either the STRIDE program or usu…

This study tests two support programs for women aged 65 and older with hormone-sensitive breast cancer who are taking aromatase inhibitors. The programs include a clinic-level geriatric assessment and support, and a telehealth coping skills training based on cognitive behavioral …

This study tests whether a gentle electrical stimulation on the ear (called taVNS) can reduce joint and muscle pain caused by aromatase inhibitors, a common breast cancer treatment. 216 women with hormone-positive breast cancer will receive either real or sham stimulation daily f…

This study tests whether acupuncture can safely reduce hot flashes in women with hormone receptor-positive breast cancer who are on hormone therapy. Sixty patients will receive either real or sham acupuncture three times a week for eight weeks, then be followed for 16 more weeks.…

This study tests whether giving atropine before treatment can prevent diarrhea in people with advanced breast cancer receiving the drug sacituzumab govitecan. About 30 participants will receive atropine alongside their cancer therapy. The goal is to improve treatment tolerance an…

This phase 3 trial tests whether CBD oil can reduce joint pain caused by aromatase inhibitors, a common hormone therapy for early breast cancer. About 130 participants will receive either CBD or a placebo for 12 weeks, then switch treatments. The study measures pain interference …

This study tests a simple home questionnaire for women with HR+HER2- advanced breast cancer who are taking CDK4/6 inhibitors and hormone therapy. The goal is to see if the questionnaire can accurately identify which patients truly need to come to the hospital for a check-up, pote…

This study will enroll 235 women with hormone receptor-positive, HER2-negative breast cancer who are taking abemaciclib after surgery. Researchers want to see if higher levels of the drug in the blood are linked to severe diarrhea, a common side effect. By understanding this link…

This study observes people with a common type of advanced breast cancer (HR+/HER2-) who are already on standard hormone therapy. Researchers use simple blood tests to look for changes in the ESR1 gene, which can make the cancer stop responding to treatment. By tracking these muta…

This study aims to understand why breast cancer in young women is often more aggressive. Researchers will look at how pregnancy and breastfeeding might influence the disease. They will collect information from 1,000 women aged 45 or younger (and a comparison group aged 55+) with …

This pilot study tests whether a biology-guided therapy recommendations report can help doctors choose treatments for advanced hormone receptor-positive breast cancer that cannot be removed by surgery or has spread. Researchers will analyze tumor tissue from 20 patients to create…

This study looks at how gut bacteria affect diarrhea and other stomach issues in people with HR+/HER2- breast cancer taking the drug abemaciclib. In the first part, researchers will collect stool samples to track bacteria changes. In the second part, a small group will try eating…

This observational study will follow 300 women aged 45-55 with hormone receptor-positive breast cancer to see if changes in a hormone called AMH can predict when they will reach menopause. Researchers will collect blood samples at seven time points and track menstrual patterns. T…

This study aims to create a simple tool (called a nomogram) that predicts the chance of breast cancer coming back in women with HR+/HER2- early-stage breast cancer. Researchers will look back at the records of 500 patients to find patterns that help personalize risk estimates. Th…

This study will follow 81 people with early-stage, hormone-positive breast cancer who are at high risk of the cancer coming back. Researchers want to see how often patients take their prescribed CDK4/6 inhibitor pills (abemaciclib or ribociclib) alongside standard hormone therapy…

This study will track gut microbiome changes in 12 women with hormone receptor-positive breast cancer starting Verzenio (abemaciclib) therapy. Participants will take either a resistant potato starch supplement or a placebo, and provide stool samples and symptom questionnaires rem…

This study looks at stored tumor samples from 70 women with a common type of breast cancer (ER-positive, HER2-negative) who received hormone therapy. Researchers want to see if two specific proteins, p-AKT and p-S6, can help tell which cancers will respond to treatment and which …

This study will analyze medical records from 100,000 people in Korea who had early-stage hormone receptor-positive, HER2-negative breast cancer and received surgery followed by other treatments. The goal is to see how often the cancer comes back and what factors might affect that…

This observational study will follow 300 premenopausal women with HR-positive early breast cancer who are already receiving ovarian function suppression (OFS) therapy as part of their routine care. Researchers want to see how many patients stop OFS within two years and why, and w…